MCL1 and neoplasm: However, S64315/MIK665 (NCT04629443, NCT03672695, NCT04702425), demonstrating activity against MCL-1, entered phase I/II clinical trials in AML, while AMG 176 (NCT02675452) and PRT1419 (NCT04543305, NCT05107856) have entered phase I. An interesting approach is to combine S64315/MIK665 with S65487 (VOB560); the latter is a selective BCL-2 inhibitor, which is also active against BCL-2 mutations such as G101V and D103Y, and is known to induce robust anti-tumor activity (NCT04702425).